We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Amgen (AMGN - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $5.25 per share, reflecting an increase of 5.6% compared to the same period last year. Revenues are forecasted to be $8.86 billion, representing a year-over-year increase of 5.6%.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Amgen metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Revenue- Product sales' stands at $8.49 billion. The estimate indicates a year-over-year change of +5.6%.
Analysts' assessment points toward 'Product Sales- Neulasta- Total' reaching $92.14 million. The estimate points to a change of -12.3% from the year-ago quarter.
The combined assessment of analysts suggests that 'Product Sales- LUMAKRAS/LUMYKRAS- Total' will likely reach $91.20 million. The estimate suggests a change of +7.3% year over year.
Analysts expect 'Product Sales- Otezla- Total' to come in at $533.54 million. The estimate suggests a change of -1.9% year over year.
It is projected by analysts that the 'Product Sales- Neulasta- ROW' will reach $23.31 million. The estimate suggests a change of -22.3% year over year.
The collective assessment of analysts points to an estimated 'Product Sales- Neulasta- U.S.' of $66.88 million. The estimate points to a change of -10.8% from the year-ago quarter.
The average prediction of analysts places 'Product Sales- Vectibix- ROW' at $135.60 million. The estimate indicates a change of -1% from the prior-year quarter.
Analysts forecast 'Product Sales- Vectibix- U.S.' to reach $141.96 million. The estimate suggests a change of +6.7% year over year.
Analysts predict that the 'Product Sales- Enbrel- U.S.' will reach $786.00 million. The estimate indicates a change of -12.9% from the prior-year quarter.
According to the collective judgment of analysts, 'Product Sales- Enbrel- ROW' should come in at $7.01 million. The estimate points to a change of +0.1% from the year-ago quarter.
The consensus among analysts is that 'Product Sales- Aranesp- ROW' will reach $251.00 million. The estimate indicates a year-over-year change of -2.3%.
Based on the collective assessment of analysts, 'Product Sales- Aranesp- U.S.' should arrive at $80.25 million. The estimate points to a change of -11.8% from the year-ago quarter.
Over the past month, Amgen shares have recorded returns of +1.5% versus the Zacks S&P 500 composite's +2.7% change. Based on its Zacks Rank #3 (Hold), AMGN will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics
In its upcoming report, Amgen (AMGN - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $5.25 per share, reflecting an increase of 5.6% compared to the same period last year. Revenues are forecasted to be $8.86 billion, representing a year-over-year increase of 5.6%.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Amgen metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Revenue- Product sales' stands at $8.49 billion. The estimate indicates a year-over-year change of +5.6%.
Analysts' assessment points toward 'Product Sales- Neulasta- Total' reaching $92.14 million. The estimate points to a change of -12.3% from the year-ago quarter.
The combined assessment of analysts suggests that 'Product Sales- LUMAKRAS/LUMYKRAS- Total' will likely reach $91.20 million. The estimate suggests a change of +7.3% year over year.
Analysts expect 'Product Sales- Otezla- Total' to come in at $533.54 million. The estimate suggests a change of -1.9% year over year.
It is projected by analysts that the 'Product Sales- Neulasta- ROW' will reach $23.31 million. The estimate suggests a change of -22.3% year over year.
The collective assessment of analysts points to an estimated 'Product Sales- Neulasta- U.S.' of $66.88 million. The estimate points to a change of -10.8% from the year-ago quarter.
The average prediction of analysts places 'Product Sales- Vectibix- ROW' at $135.60 million. The estimate indicates a change of -1% from the prior-year quarter.
Analysts forecast 'Product Sales- Vectibix- U.S.' to reach $141.96 million. The estimate suggests a change of +6.7% year over year.
Analysts predict that the 'Product Sales- Enbrel- U.S.' will reach $786.00 million. The estimate indicates a change of -12.9% from the prior-year quarter.
According to the collective judgment of analysts, 'Product Sales- Enbrel- ROW' should come in at $7.01 million. The estimate points to a change of +0.1% from the year-ago quarter.
The consensus among analysts is that 'Product Sales- Aranesp- ROW' will reach $251.00 million. The estimate indicates a year-over-year change of -2.3%.
Based on the collective assessment of analysts, 'Product Sales- Aranesp- U.S.' should arrive at $80.25 million. The estimate points to a change of -11.8% from the year-ago quarter.
View all Key Company Metrics for Amgen here>>>Over the past month, Amgen shares have recorded returns of +1.5% versus the Zacks S&P 500 composite's +2.7% change. Based on its Zacks Rank #3 (Hold), AMGN will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .